1
Mark Munson, David A Mareska, Youngboo Kim, Robert D Gronenberg, James P Rizzi, Martha Rodriguez, Ganghyeok Kim, Guy Vigers, Chang Rao, Devan Balachari, Darren Harvey: P38 inhibitors and methods of use thereof. Array BioPharma, John R Moore Esq, Viksnins Harris & Padys PLLP, September 21, 2010: US07799782 (180 worldwide citation)

This invention relates to inhibitors of p38 and methods of utilizing the inhibitors and pharmaceutical compositions thereof in the treatment and prevention of various disorders mediated by p38.


2
Blatt Lawrence M, Wenglowsky Steven Mark, Andrews Steven Wade, Jiang Yutong, Kennedy April Layne, Condroski Kevin Ronald, Josey John Anthony, Stengel Peter John, Madduru Machender R, Doherty George Andrew, Woodard Benjamin T: Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication. Intermune, Array Biopharma, MALLON Joseph J, April 28, 2005: WO/2005/037214 (115 worldwide citation)

The present invention provides compounds of the general formulas I-IX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The present invention further provides treatment methods, including methods of treating a hepatitis C virus infection and methods of t ...


3

4
Blake James F, Boyd Steven Armen, Cohen Frederick, de, Meese Jason, Fong Kin Chiu, Gaudino John J, Kaplan Tomas, Marlow Allison L, Seo Jeongbeob, Thomas Allen A, Tian Hongqi, Young Wendy B: Heterobicyclic pyrazole compounds and methods of use. Array Biopharma, Genentech, Blake James F, Boyd Steven Armen, Cohen Frederick, de, Meese Jason, Fong Kin Chiu, Gaudino John J, Kaplan Tomas, Marlow Allison L, Seo Jeongbeob, Thomas Allen A, Tian Hongqi, Young Wendy B, HARRIS Robert J, September 13, 2007: WO/2007/103308 (60 worldwide citation)

Compounds of Formulas (Ia) and (Ib), and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, ...


5
Blatt Lawrence M, Seiwert Scott, Beigelman Leonid, Kercher Timothy, Kennedy April L, Andrews Steven W: Novel inhibitors of hepatitis c virus replication. Intermune, Array Biopharma, Blatt Lawrence M, Seiwert Scott, Beigelman Leonid, Kercher Timothy, Kennedy April L, Andrews Steven W, MALLON Joseph J, January 10, 2008: WO/2008/005511 (58 worldwide citation)

The embodiments provide compounds of the general Formula (I), as well as compositions, including pharmaceutical compositions, comprising a, subject compound. The embodiments provide compounds of the general Formula (II), as well as compositions, including pharmaceutical compositions, comprising a su ...


6
Blatt Lawrence M, Pan Lin, Seiwert Scott, Andrews Steven W, Martin Pierre, Schumacher Andreas, Beigelman Leonid, Liu Jyanwei, Condroski Kevin, Jiang Yutong, Kaus Robert, Kennedy April, Kercher Timothy, Lyon Michael, Wang bin: Novel macrocyclic inhibitors of hepatitis c virus replication. Intermune, Array Biopharma, Blatt Lawrence M, Pan Lin, Seiwert Scott, Andrews Steven W, Martin Pierre, Schumacher Andreas, Beigelman Leonid, Liu Jyanwei, Condroski Kevin, Jiang Yutong, Kaus Robert, Kennedy April, Kercher Timothy, Lyon Michael, Wang bin, MALLON Joseph J, November 13, 2008: WO/2008/137779 (54 worldwide citation)

The embodiments provide macrocyclic compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treatin ...


7
Beigelman Leonid, Seiwert Scott D, Blatt Lawrence M, Andrews Steven, Haas Julia: Compounds and methods for inhibiting hepatitis c viral replication. Intermune, Array Biopharma, Beigelman Leonid, Seiwert Scott D, Blatt Lawrence M, Andrews Steven, Haas Julia, MALLON Joseph J, April 19, 2007: WO/2007/044893 (54 worldwide citation)

Macrocyclic compounds having the structures described herein arc useful for inhibiting replication of the hepatitis C virus (HCV). In preferred embodiments, the compounds are active against both the NS3 protease and the NS3 helicase of HCV. Formulae (I), (II), (III), (IV) and (V).


8
Andrews Steven W, Seiwert Scott, Beigelman Leonid, Blatt Lawrence, Buckman Brad: Novel peptide inhibitors of hepatitis c virus replication. Intermune, Array Biopharma, Andrews Steven W, Seiwert Scott, Beigelman Leonid, Blatt Lawrence, Buckman Brad, HART Daniel, November 20, 2008: WO/2008/141227 (52 worldwide citation)

The embodiments provide compounds of the general Formula (I), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula (II), as well as compositions, including pharmaceutical compositions, comprising a sub ...


9
Allen Shelley, Greschuk Julie Marie, Kallan Nicholas C, Marmsäter Fredrik P, Munson Mark C, Rizzi James P, Robinson John E, Schlachter Stephen T, Topalov George T, Zhao Qian, Lyssikatos Joseph P: Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors. Array Biopharma, Allen Shelley, Greschuk Julie Marie, Kallan Nicholas C, Marmsäter Fredrik P, Munson Mark C, Rizzi James P, Robinson John E, Schlachter Stephen T, Topalov George T, Zhao Qian, Lyssikatos Joseph P, HARRIS Robert J, October 16, 2008: WO/2008/124323 (48 worldwide citation)

Compounds of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5 R6, R7 and R8 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class 3 and class 5 receptor tyrosine kinases. Particular compounds of this invention have also ...


10
ALLEN SHELLEY: Triazolopyridine compounds as pim kinase inhibitors. ARRAY BIOPHARMA, Harris Robert J, February 25, 2010: WO/2010/022081 (38 worldwide citation)

Compounds of Formula (I): I in which B, R1, R1a, R2, R3, R4, R5, R6, R7, R10 and R11 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.



Click the thumbnails below to visualize the patent trend.